Aequus Pharmaceuticals Inc $ 0.08 0 (-4.24%)
Volume:
7,399
Avg Vol (1m):
21,562
Market Cap $:
7.91 Mil
Enterprise Value $:
9.46 Mil
P/E (TTM):
0.00
P/B:
0.00
Financial Strength | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.14 | ||
| Equity-to-Asset | -1.05 | ||
| Debt-to-Equity | -1.7 | ||
| Debt-to-EBITDA | -1.77 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | -24.64 | ||
| Beneish M-Score | -6.12 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -58.58 | ||
| Net Margin % | -114.69 | ||
| ROA % | -113.39 | ||
| ROC (Joel Greenblatt) % | -243.19 | ||
| 3-Year Revenue Growth Rate | 10.1 | ||
| 3-Year EBITDA Growth Rate | 32.8 | ||
| 3-Year EPS without NRI Growth Rate | 26.3 |
AQSZF
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PS Ratio | 3.36 | ||
| EV-to-EBIT | -7.1 | ||
| EV-to-EBITDA | -8.68 | ||
| EV-to-Revenue | 5.82 | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Days Sales Outstanding | 99.17 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Earnings Yield (Greenblatt) % | -14.05 |